* Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post e...
* Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and...
Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership ...
* Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater Ch...
* End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding ...
* Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to util...
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of...
Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufa...
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added ...
New translational data demonstrate that BRII-179-induced immune responses are associated with high ...
DURHAM, N.C. and BEIJING, May 14, 2024 /PRNewswire/ -- Brii Biosciences Limited
2024-05-14 07:27
3419
Transitioning HBV cure programs into multiple late-stage combination studies with interim results t...
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and roy...
DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited
2024-01-03 20:00
6048
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased an...
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased an...
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at ...
First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HB...
Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to ac...
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in ...